(Q38075117)

28 August 2017

1 reference

title

Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus (English)

1 reference

28 August 2017

1 reference

2

P S Leung

1 reference

28 August 2017

L H Chen

1

1 reference

28 August 2017

publication date

6 February 2013

1 reference

Diabetes, Obesity and Metabolism

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

392-402

1 reference

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

28 August 2017

cites work

1 reference

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review

21 January 2018

1 reference

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

A novel SGLT is expressed in the human kidney

21 January 2018

1 reference

SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose

21 January 2018

1 reference

Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter.

21 January 2018

1 reference

A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol

21 January 2018

1 reference

New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families

21 January 2018

1 reference

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

Long-term outcome of renal glucosuria type 0: the original patient and his natural history

21 January 2018

1 reference

Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat.

21 January 2018

1 reference

Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

21 January 2018

1 reference

21 January 2018

1 reference

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states

21 January 2018

1 reference

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors

21 January 2018

1 reference

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

21 January 2018

1 reference

(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

21 January 2018

1 reference

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes

21 January 2018

1 reference

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

21 January 2018

1 reference

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Diabetes mellitus and genetically programmed defects in beta-cell function

21 January 2018

1 reference

Inflammation and metabolic disorders

21 January 2018

1 reference

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

21 January 2018

1 reference

Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice

21 January 2018

1 reference

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

21 January 2018

1 reference

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

21 January 2018

1 reference

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function

21 January 2018

1 reference

Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus

21 January 2018

1 reference

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

21 January 2018

1 reference

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

21 January 2018

1 reference

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

Effects of SGLT2 inhibitors on cardiovascular outcomes

21 January 2018

1 reference

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

21 January 2018

1 reference

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes

21 January 2018

1 reference

Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12064

1 reference

28 August 2017

1 reference